Macro Group registers 182% YoY growth consolidated profit in Q1
Updated 5/29/2022 3:04:00 PM
Arab Finance: Macro Group Pharmaceutical (Macro Capital) (MCRO) has reported a 182% year-on-year (YoY) surge in consolidated profits attributable to the parent company during the first quarter (Q1) of 2022, according to the consolidated financial statement filed to the Egyptian Exchange (EGX) on May 29th.
The group recorded a consolidated net profit excluding minority interest of EGP 30.668 million in Q1 2022, compared to EGP 10.87 million in Q1 2021.
Consolidated sales soared to EGP 134.913 million in Q1 2022 from EGP 117.922 million in Q1 2021.
Meanwhile, standalone net profit after tax increased to EGP 31.089 million in the three-month period ended March 31st from EGP 11.693 million in the comparative period last year, the standalone financial statement showed.
Founded in 2002, Macro Group is a leading Egyptian cosmeceutical company based in Cairo.
